Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.

BMC Cancer · 2025 · PMC12882522 · PMID 41353112

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.05actually significant

When stratified by EGFR mutation status, immunotherapy was associated with significantly longer OS in the EGFR wild-type subgroup ( p = 0.004) and showed a trend toward improved OS in the EGFR-mutant subgroup ( p = 0.05) (Supplementary Fig.

also in 33,481 other papers

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

Intracranial and extracranial PFS were numerically longer in the immunotherapy group but did not reach statistical significance (iPFS: 10.4 vs. 9.6 months, p = 0.09; ePFS: 7.8 vs. 7.1 months, p = 0.06).

also in 75,868 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.